Drug intelligence / Profile preview

KSI-103

Development stage: Preclinical
Lead developer: Kodiak Sciences
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravitreal

Overview

KSI-103 is a preclinical-stage bispecific biologic candidate developed by Kodiak Sciences for the treatment of chronic inflammatory ocular diseases. It is designed as a fusion protein consisting of an interleukin-1 (IL-1) trap and an anti-interleukin-6 (IL-6) antibody. By simultaneously targeting these two key pro-inflammatory cytokines, KSI-103 aims to address the complex inflammatory pathways that drive retinal and other ocular pathologies. The drug is intended for intravitreal administration, leveraging Kodiak's focus on long-acting ophthalmic therapies.

Targets

IL-6 (Interleukin 6)IL1A (Interleukin 1 alpha)

Beyond the preview

Go deeper on KSI-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KSI-103.

Explore the full profile